Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K5 | Q99683 | 9/20 | 0.89 |
| ▸ | HIF1AN | Q9NWT6 | 1/20 | 0.81 |
| ▸ | MEN1 | O00255 | 3/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.70 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.70 |
| ▸ | PKM | P14618 | 1/20 | 0.70 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.70 |
| ▸ | STAT3 | P40763 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | POLB | P06746 | 2/20 | 0.61 |
| ▸ | MAPT | P10636 | 2/20 | 0.61 |
| ▸ | HPGD | P15428 | 2/20 | 0.61 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.61 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.61 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8593141 | 1.00 | MAP3K5 (0.89) | MAP3K5HIF1ANMEN1KMT2AMCL1 | |
| SCHEMBL3901648 | 1.00 | MAP3K5 (0.89) | MAP3K5HIF1ANMEN1KMT2AMCL1 | |
| SCHEMBL14860803 | 0.91 | MAP3K5 (0.77) | MAP3K5HIF1ANMEN1KMT2AMCL1 | |
| SCHEMBL14867586 | 0.91 | MAP3K5 (0.77) | MAP3K5HIF1ANMEN1KMT2AMCL1 | |
| SCHEMBL14860805 | 0.91 | MAP3K5 (0.77) | MAP3K5HIF1ANMEN1KMT2AMCL1 | |
| SCHEMBL8290210 | 0.91 | HIF1AN (0.83) | MAP3K5HIF1ANMEN1KMT2AMCL1 | |
| SCHEMBL3905770 | 0.91 | HIF1AN (0.83) | MAP3K5HIF1ANMEN1KMT2AMCL1 | |
| SCHEMBL3905768 | 0.91 | HIF1AN (0.83) | MAP3K5HIF1ANMEN1KMT2AMCL1 | |
| SCHEMBL23433501 | 0.90 | HIF1AN (0.81) | MAP3K5HIF1ANMEN1KMT2AMCL1 | |
| Claficapavir SCHEMBL6789043 | 0.90 | HIF1AN (1.00) | MAP3K5HIF1ANMEN1KMT2AMCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137644-A1 | RHODANINE COMPOSITIONS FOR USE AS ANTIVIRAL AGENTS | RIGEL PHARMACEUTICALS, INC. (US) | 2009-05-28 | — | — | US | claimed |
| US-7566732-B2 | Rhodanine compositions for use as antiviral agents | RIGEL PHARMACEUTICALS, INC. (US) | 2009-07-28 | — | — | US | disclosed |
| US-20090137644-A1 | RHODANINE COMPOSITIONS FOR USE AS ANTIVIRAL AGENTS | RIGEL PHARMACEUTICALS, INC. (US) | 2009-05-28 | — | — | US | disclosed |
| US-20060276520-A1 | Rhodanine derivatives and pharmaceutical compositions containing them | RIGEL PHARMACEUTICALS, INC. (US) | 2006-12-07 | — | — | US | disclosed |
| WO-1998053790-A2 | COMPOUNDS THAT INHIBIT THE BINDING OF VASCULAR ENDOTHELIAL GROWTH FACTOR TO ITS RECEPTORS | TEXAS BIOTECHNOLOGY CORPORATION (US) | 1998-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276520-A1 | Rhodanine derivatives and pharmaceutical compositions containing them | UBQLN1, UBQLN2, UBE2G2 | MAP3K5 1092/4885HIF1AN 647/4885MEN1 1562/4885 |
| US-20090137644-A1 | RHODANINE COMPOSITIONS FOR USE AS ANTIVIRAL AGENTS | RBX1, ITCH, UBQLN1 | MAP3K5 1460/4885HIF1AN 714/4885MEN1 2869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.